Therefore, we suggest that even if the primary focus is the right-sided colon, an anti-EGFR antibody plus CAT should be introduced for mCRC patients who require quick and marked reduction of metastatic lesions that cause concomitant symptoms such as ileus or pain. The gene discussed is EGFR; the disease is ileus.